 Thanks, everybody. It's a great honor to accept this gift to supporting our research. So my research in brain disease is called Cerebral Covenoma Affirmation. It depends on which condition you go. This can also be named as angioma or covenoma. The disease can be described as a burly-like or grip cluster of vessels in the venous side of the brain. So there's a vessel extremely thin. The two potential problems, one is this thin vessel break. Then, therefore, cost of strokes. I see everybody here now what's the further consequence of the stroke. And the second problem will be when the lesion gets too big, is the pressure along the neuronal tissues and also dislocated neuronal tissue that causes left-sliding neuronal defects. But so far, no drug treatment available for this disease. The only available treatment for this disease is neurosurgery. But it depends on location or lesions and the number of lesions in the brain. Not all patients have this option. It is open to them. So for the understanding of molecular signaling, molecular understanding of this disease starts about 20 years ago in the late 1990s and early 2000s. People start now in the three-gen system, one system, two system, three can cause this disease. So I have been in the field for a little over 10 years now. So we've been using multiple experimental model systems to understand how this disease gene works. So in the past few years, we understand use the disease model and understand a few enzymes working with disease genes can promote the disease progression. So right now, we are working harder to study trying to find a chemical compound or block those enzymes, therefore, to block this disease. So this is, I think, the gift for partly supporting this effort we have been doing there. In this community, I always try to get one message across. It is one out of 200 people in general population have this disease in their brain, but only a smaller population of percentage of people will have the symptom of the disease problem. So therefore, this disease is classified as a rare disease. In this country, this disease is not very well-recognized, even among clinicians in the research on your neurologic disease area. So I think this is a very important space for the foundation like this community. A vital role for us is to study this disease and also for the patients with this disease, as often disease. So with that, it's acceptable again.